Europe’s medical devices industry saw a drop of 3.8% in overall deal activity during Q4 2019, when compared to the four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 76 deals worth $5.72bn were announced for the region during Q4 2019, against the last four-quarter average of 79 deals.
Of all the deal types, venture financing saw most activity in Q4 2019 with 39, representing a 51.3% share for the region.
In second place was M&A with 31 deals, followed by private equity deals with six transactions, respectively capturing a 40.8% and 7.9% share of the overall deal activity for the quarter.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $5.4bn, followed by venture financing deals totalled $319.18m.
Europe medical devices industry deals in Q4 2019: Top deals
The top five medical devices deals accounted for 97.6% of the overall value during Q4 2019.
The combined value of the top five medical devices deals stood at $5.58bn, against the overall value of $5.72bn recorded for the quarter.
The top five medical devices industry deals of Q4 2019 tracked by GlobalData were:
2) The $80.25m venture financing of Impulse Dynamics by Abiomed, Acorn Bioventures, Amzak Health, Kennedy Lewis Investment Management, Minth Investment, Wellington ManagementLLP and Zoll Medical
3) BNP Paribas Developpement, BPI France, CapDecisif Management, CM-CIC Innovation, European Investment Fund, M&L Investments, Omnes Capital, Sofinnova Partners and Valquest Capital Management’s $42.91m venture financing of Tissium
4) The $34.15m venture financing of Diabeloop by AGIR a dom, Air Liquide Venture Capital, Cemag Invest, Centre d’Etude et de Recheche pour l’ Intensification du Traitement du Diabete, Credit Agricole, Kreaxi, Odyssee Venture, Sofimac Innovation and Supernova Invest
5) Ajax Health’s venture financing of EPMap-System GmbH & Co for $25m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.